Do analysts rate NRSN or TELO?

NeuroSense Therapeutics currently has a consensus price target of $8.50, suggesting a potential upside of 956.43%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe NeuroSense Therapeutics is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroSense Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation and earnings, NRSN or TELO?

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeuroSense Therapeutics N/A N/A -$11.12M -$0.54 N/A Telomir Pharmaceuticals N/A N/A -$10.41M -$0.29 N/A

Is NRSN or TELO more profitable?

NeuroSense Therapeutics' return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets NeuroSense Therapeutics N/A N/A N/A Telomir Pharmaceuticals N/A -201.23% -172.71%

Does the media favor NRSN or TELO?

In the previous week, NeuroSense Therapeutics had 1 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 3 mentions for NeuroSense Therapeutics and 2 mentions for Telomir Pharmaceuticals. NeuroSense Therapeutics' average media sentiment score of 1.97 beat Telomir Pharmaceuticals' score of 0.00 indicating that NeuroSense Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroSense Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Telomir Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, NRSN or SXTC?

China SXT Pharmaceuticals has higher revenue and earnings than NeuroSense Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeuroSense Therapeutics N/A N/A -$11.12M -$0.54 N/A China SXT Pharmaceuticals $1.74M 48.98 -$3.30M N/A N/A

Is NRSN or SXTC more profitable?

Company Net Margins Return on Equity Return on Assets NeuroSense Therapeutics N/A N/A N/A China SXT Pharmaceuticals N/A N/A N/A

Is ANIX or NRSN more profitable?

NeuroSense Therapeutics' return on equity of 0.00% beat Anixa Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Anixa Biosciences N/A -71.12% -62.88% NeuroSense Therapeutics N/A N/A N/A

Does the media prefer ANIX or NRSN?

In the previous week, Anixa Biosciences had 3 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 6 mentions for Anixa Biosciences and 3 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 1.97 beat Anixa Biosciences' score of 1.03 indicating that NeuroSense Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anixa Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeuroSense Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation & earnings, NRSN or BMEA?

Biomea Fusion is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeuroSense Therapeutics N/A N/A -$11.12M -$0.54 N/A Biomea Fusion N/A N/A -$61.80M -$0.68 N/A

Is NRSN or BMEA more profitable?

NeuroSense Therapeutics' return on equity of 0.00% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets NeuroSense Therapeutics N/A N/A N/A Biomea Fusion N/A -265.37% -103.96%

Does the media favor NRSN or BMEA?

In the previous week, NeuroSense Therapeutics had 2 more articles in the media than Biomea Fusion. MarketBeat recorded 3 mentions for NeuroSense Therapeutics and 1 mentions for Biomea Fusion. NeuroSense Therapeutics' average media sentiment score of 1.97 beat Biomea Fusion's score of 0.00 indicating that NeuroSense Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroSense Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Biomea Fusion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

NeuroSense Therapeutics (NRSN) Competitors

$0.80 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$0.80 0.00 (-0.32%)

As of 06/18/2026 07:39 PM Eastern

Compare

NRSN vs. TELO, SXTC, ANIX, ATRA, and BMEA

Should you buy NeuroSense Therapeutics stock or one of its competitors? MarketBeat compares NeuroSense Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NeuroSense Therapeutics include Telomir Pharmaceuticals (TELO), China SXT Pharmaceuticals (SXTC), Anixa Biosciences (ANIX), Atara Biotherapeutics (ATRA), and Biomea Fusion (BMEA). These companies are all part of the "pharmaceutical products" industry.

How does NeuroSense Therapeutics compare to Telomir Pharmaceuticals?

NeuroSense Therapeutics (NASDAQ:NRSN) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A

NeuroSense Therapeutics has a beta of 1.56, indicating that its share price is 56% more volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.24, indicating that its share price is 124% less volatile than the broader market.

NeuroSense Therapeutics currently has a consensus price target of $8.50, suggesting a potential upside of 956.43%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe NeuroSense Therapeutics is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, NeuroSense Therapeutics had 1 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 3 mentions for NeuroSense Therapeutics and 2 mentions for Telomir Pharmaceuticals. NeuroSense Therapeutics' average media sentiment score of 1.97 beat Telomir Pharmaceuticals' score of 0.00 indicating that NeuroSense Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroSense Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Telomir Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

1.0% of NeuroSense Therapeutics shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

NeuroSense Therapeutics' return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%

Summary

NeuroSense Therapeutics beats Telomir Pharmaceuticals on 12 of the 14 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to China SXT Pharmaceuticals?

NeuroSense Therapeutics (NASDAQ:NRSN) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
China SXT Pharmaceuticals	N/A	N/A	N/A

China SXT Pharmaceuticals has higher revenue and earnings than NeuroSense Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A
China SXT Pharmaceuticals	$1.74M	48.98	-$3.30M	N/A	N/A

NeuroSense Therapeutics has a beta of 1.56, indicating that its stock price is 56% more volatile than the broader market. Comparatively, China SXT Pharmaceuticals has a beta of 1.91, indicating that its stock price is 91% more volatile than the broader market.

NeuroSense Therapeutics currently has a consensus target price of $8.50, suggesting a potential upside of 956.43%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe NeuroSense Therapeutics is more favorable than China SXT Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.0% of NeuroSense Therapeutics shares are owned by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by company insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, NeuroSense Therapeutics had 3 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 3 mentions for NeuroSense Therapeutics and 0 mentions for China SXT Pharmaceuticals. NeuroSense Therapeutics' average media sentiment score of 1.97 beat China SXT Pharmaceuticals' score of 0.00 indicating that NeuroSense Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
NeuroSense Therapeutics	Very Positive
China SXT Pharmaceuticals	Neutral

Summary

NeuroSense Therapeutics beats China SXT Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Anixa Biosciences?

Anixa Biosciences (NASDAQ:ANIX) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Anixa Biosciences has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, NeuroSense Therapeutics has a beta of 1.56, indicating that its share price is 56% more volatile than the broader market.

NeuroSense Therapeutics' return on equity of 0.00% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-71.12%	-62.88%
NeuroSense Therapeutics	N/A	N/A	N/A

Anixa Biosciences presently has a consensus target price of $8.50, suggesting a potential upside of 192.10%. NeuroSense Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 956.43%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe NeuroSense Therapeutics is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Anixa Biosciences has higher revenue and earnings than NeuroSense Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	471.42	-$10.93M	-$0.31	N/A
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A

29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are owned by institutional investors. 26.4% of Anixa Biosciences shares are owned by insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Anixa Biosciences had 3 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 6 mentions for Anixa Biosciences and 3 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 1.97 beat Anixa Biosciences' score of 1.03 indicating that NeuroSense Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anixa Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeuroSense Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

NeuroSense Therapeutics beats Anixa Biosciences on 9 of the 15 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Atara Biotherapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are held by institutional investors. 41.2% of Atara Biotherapeutics shares are held by insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

NeuroSense Therapeutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. NeuroSense Therapeutics' return on equity of 0.00% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%
NeuroSense Therapeutics	N/A	N/A	N/A

Atara Biotherapeutics has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market. Comparatively, NeuroSense Therapeutics has a beta of 1.56, suggesting that its stock price is 56% more volatile than the broader market.

Atara Biotherapeutics has higher revenue and earnings than NeuroSense Therapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.75	$32.69M	-$0.67	N/A
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A

In the previous week, NeuroSense Therapeutics had 3 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 3 mentions for NeuroSense Therapeutics and 0 mentions for Atara Biotherapeutics. NeuroSense Therapeutics' average media sentiment score of 1.97 beat Atara Biotherapeutics' score of -0.35 indicating that NeuroSense Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Atara Biotherapeutics	Neutral
NeuroSense Therapeutics	Very Positive

Atara Biotherapeutics presently has a consensus target price of $9.50, suggesting a potential downside of 5.66%. NeuroSense Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 956.43%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe NeuroSense Therapeutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Summary

NeuroSense Therapeutics beats Atara Biotherapeutics on 12 of the 16 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Biomea Fusion?

NeuroSense Therapeutics (NASDAQ:NRSN) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

1.0% of NeuroSense Therapeutics shares are owned by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by company insiders. Comparatively, 10.6% of Biomea Fusion shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

NeuroSense Therapeutics' return on equity of 0.00% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
Biomea Fusion	N/A	-265.37%	-103.96%

Biomea Fusion is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A

In the previous week, NeuroSense Therapeutics had 2 more articles in the media than Biomea Fusion. MarketBeat recorded 3 mentions for NeuroSense Therapeutics and 1 mentions for Biomea Fusion. NeuroSense Therapeutics' average media sentiment score of 1.97 beat Biomea Fusion's score of 0.00 indicating that NeuroSense Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroSense Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Biomea Fusion	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NeuroSense Therapeutics currently has a consensus target price of $8.50, indicating a potential upside of 956.43%. Biomea Fusion has a consensus target price of $8.50, indicating a potential upside of 620.34%. Given NeuroSense Therapeutics' higher probable upside, equities analysts plainly believe NeuroSense Therapeutics is more favorable than Biomea Fusion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

NeuroSense Therapeutics has a beta of 1.56, indicating that its stock price is 56% more volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.31, indicating that its stock price is 131% less volatile than the broader market.

Summary

NeuroSense Therapeutics beats Biomea Fusion on 11 of the 14 factors compared between the two stocks.

Get NeuroSense Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NRSN vs. The Competition

Export

Metric	NeuroSense Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$26.20M	$3.41B	$6.43B	$12.60B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-1.49	10.86	20.90	22.41
Price / Sales	N/A	320.32	529.30	111.09
Price / Cash	N/A	56.54	27.92	37.84
Price / Book	-16.09	8.15	10.81	6.60
Net Income	-$11.12M	$23.91M	$3.57B	$337.10M
7 Day Performance	9.44%	2.57%	0.72%	0.83%
1 Month Performance	4.09%	0.69%	0.41%	2.25%
1 Year Performance	-65.76%	55.09%	29.34%	36.14%

NeuroSense Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NRSN NeuroSense Therapeutics	4.4422 of 5 stars	$0.80 flat	$8.50 +956.4%	-65.8%	$26.20M	N/A	N/A	10	News Coverage Positive News Upcoming Earnings Insider Trade Gap Down
TELO Telomir Pharmaceuticals	0.4599 of 5 stars	$1.32 +1.9%	N/A	-19.3%	$90.45M	N/A	N/A	1
SXTC China SXT Pharmaceuticals	0.7246 of 5 stars	$2.34 -0.3%	N/A	-99.2%	$89.63M	$1.74M	N/A	90	Gap Up
ANIX Anixa Biosciences	3.708 of 5 stars	$2.63 +6.0%	$8.50 +223.2%	-13.9%	$89.47M	$210K	N/A	5	News Coverage Positive News Analyst Forecast Gap Down
ATRA Atara Biotherapeutics	1.2284 of 5 stars	$9.75 -2.1%	$9.50 -2.6%	+26.8%	$87.85M	$120.77M	N/A	330

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NRSN) was last updated on 6/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeuroSense Therapeutics (NRSN) Competitors

NRSN vs. TELO, SXTC, ANIX, ATRA, and BMEA

How does NeuroSense Therapeutics compare to Telomir Pharmaceuticals?

Summary

How does NeuroSense Therapeutics compare to China SXT Pharmaceuticals?

Summary

How does NeuroSense Therapeutics compare to Anixa Biosciences?

Summary

How does NeuroSense Therapeutics compare to Atara Biotherapeutics?

Summary

How does NeuroSense Therapeutics compare to Biomea Fusion?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN vs. The Competition

NeuroSense Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeuroSense Therapeutics (NRSN) Competitors

NRSN vs. TELO, SXTC, ANIX, ATRA, and BMEA

How does NeuroSense Therapeutics compare to Telomir Pharmaceuticals?

Which has better valuation and earnings, NRSN or TELO?

Which has more risk and volatility, NRSN or TELO?

Do analysts rate NRSN or TELO?

Does the media favor NRSN or TELO?

Do insiders & institutionals hold more shares of NRSN or TELO?

Is NRSN or TELO more profitable?

Summary

How does NeuroSense Therapeutics compare to China SXT Pharmaceuticals?

Is NRSN or SXTC more profitable?

Which has preferable valuation & earnings, NRSN or SXTC?

Which has more volatility & risk, NRSN or SXTC?

Do analysts rate NRSN or SXTC?

Do institutionals & insiders hold more shares of NRSN or SXTC?

Does the media favor NRSN or SXTC?

Summary

How does NeuroSense Therapeutics compare to Anixa Biosciences?

Which has more risk and volatility, ANIX or NRSN?

Is ANIX or NRSN more profitable?

Do analysts prefer ANIX or NRSN?

Which has preferable valuation & earnings, ANIX or NRSN?

Do institutionals & insiders have more ownership in ANIX or NRSN?

Does the media prefer ANIX or NRSN?

Summary

How does NeuroSense Therapeutics compare to Atara Biotherapeutics?

Do insiders & institutionals hold more shares of ATRA or NRSN?

Is ATRA or NRSN more profitable?

Which has more volatility & risk, ATRA or NRSN?

Which has higher earnings & valuation, ATRA or NRSN?

Does the media prefer ATRA or NRSN?

Do analysts recommend ATRA or NRSN?

Summary

How does NeuroSense Therapeutics compare to Biomea Fusion?

Do institutionals & insiders hold more shares of NRSN or BMEA?

Is NRSN or BMEA more profitable?

Which has better valuation & earnings, NRSN or BMEA?

Does the media favor NRSN or BMEA?

Do analysts rate NRSN or BMEA?

Which has more risk and volatility, NRSN or BMEA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN vs. The Competition

NeuroSense Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools